ଫେକ୍ସିନିଡାଜୋଲ

Fexinidazole
Clinical data
Synonyms	Fexinidazole Winthrop; HOE 239;
data	US DailyMed: Fexinidazole;
Routes of; administration	By mouth
ATC code	P01CA03 (WHO) ;
Legal status
Legal status	US: ℞-only ;
Identifiers
	IUPAC name 1-Methyl-2-{[4-(methylsulfanyl)phenoxy]methyl}-5-nitro-1H-imidazole;
CAS Number	59729-37-2;
PubChem CID	68792;
DrugBank	DB12265;
ChemSpider	62032;
UNII	306ERL82IR;
KEGG	D11252;
ChEMBL	CHEMBL1631694;
ECHA InfoCard	100.207.619
Chemical and physical data
Formula	C12H13N3O3S
Molar mass	୨୭୯.୩୧ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [O-][N+](=O)c1cnc(n1C)COc2ccc(SC)cc2;
	InChI InChI=1S/C12H13N3O3S/c1-14-11(13-7-12(14)15(16)17)8-18-9-3-5-10(19-2)6-4-9/h3-7H,8H2,1-2H3; Key:MIWWSGDADVMLTG-UHFFFAOYSA-N;

ଫେକ୍ସିନିଡାଜୋଲ ଏକ ଔଷଧ ଯାହା ଟ୍ରିପାନୋସୋମା ବ୍ରୁସେଇ ଗାମ୍ବିଏନ୍ସଦ୍ୱାରା ହେଉଥିବା ଆଫ୍ରିକୀୟ ଟ୍ରାଇପାନୋସୋମାସିସ୍ (ଶୋଇବା ରୋଗ) ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବ‌ହୃତ ହୁଏ | ^[୩] ଏହା ପ୍ରଥମ ଏବଂ ଦ୍ୱିତୀୟ ପର୍ଯ୍ୟାୟ ରୋଗ ବିରୁଦ୍ଧରେ ପ୍ରଭାବଶାଳୀ ହୁଏ | ^[୪] ଚାଗାସ୍ ରୋଗରେ ଏହାର ବ୍ୟବହାରକୁ ମଧ୍ୟ କିଛି ସମର୍ଥନ କରେ | ^[୫] ଏହା ପାଟିରେ ଦିଆଯାଏ | ^[୬]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଇ, ବାନ୍ତି, ମୁଣ୍ଡବିନ୍ଧା ଏବଂ ଶୋଇବାରେ ଅସୁବିଧା ହୋଇପାରେ | ^[୭] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଲଙ୍ଗ କ୍ୟୁଟି ବିସ୍ତାର (QT), ସାଇକୋସିସ୍ ଏବଂ ନିମ୍ନ ଶ୍ୱେତ ରକ୍ତକଣିକା ହୋଇପାରେ | ^[୮] ଗର୍ଭାବସ୍ଥାରେ କିମ୍ବା ସ୍ତନ୍ୟପାନ ସମୟରେ ବ୍ୟବହାର ସୁରକ୍ଷିତ କି ନାହିଁ ତାହା ଅସ୍ପଷ୍ଟ ଅଟେ | ^[୯] ଆଣ୍ଟିପାରାସାଇଟିକ ଓ ନାଇଟ୍ରୋଇମିଡାଜୋଲ ଶ୍ରେଣୀରେ ଫେକ୍ସିନିଡାଜୋଲ ଅଛି | ^[୫] ପରଜୀବୀମାନଙ୍କ ମଧ୍ୟରେ ଥିବା କିଛି ଏଞ୍ଜାଇମର ପରିବର୍ତ୍ତନ କରି ଏହା କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ବୋଲି ବିଶ୍ୱାସ କରାଯାଏ ଯାହାଦ୍ୱାରା ସେମାନଙ୍କର ମୃତ୍ୟୁ ଘଟିଥାଏ। ^[୧୦]

ଫେକ୍ସିନିଡାଜୋଲକୁ ପ୍ରଥମେ ୧୯୭୮ ମସିହାରେ ବର୍ଣ୍ଣନା କରାଯାଇଥିଲା |^[୧୧] ୨୦୧୮ ମସିହାରେ ୟୁରୋପିଆନ ମେଡିସିନ ଏଜେନ୍ସି ଏହା ବିଷୟରେ ଏକ ସକରାତ୍ମକ ମତ ଏଇଥିଲେ । ^[୭] ବିଶ୍ୱ ସ୍ୱାସ୍ଥ୍ୟ ସଂଗଠନର ଅତ୍ୟାବଶ୍ୟକୀୟ ଔଷଧ ତାଲିକାରେ ଏହାର ନାମ ଅଛି ।^[୧୨] ଶୋଇବା ରୋଗ ବିଷୟରେ ବିକାଶ ପାଇଁ ଅବ‌ହେଳିତ ରୋଗ ପାଇଁ ଔଷଧ ଓ ସାନୋଫିଙ୍କଦ୍ୱାରା ଅର୍ଥ ପ୍ରଦାନ କରାଯାଇଥିଲା | ^[୧୩]

ଆଧାର[ସମ୍ପାଦନା]

↑ "Fexinidazole: FDA-Approved Drugs". U.S. Food and Drug Administration. Retrieved 16 July 2021.
↑ "Fexinidazole tablet". DailyMed. Retrieved 20 August 2021.
↑ DIMITROVA, Elena Kostadinova (22 January 2019). "Fexinidazole Winthrop H-W-2320". European Medicines Agency (in ଇଂରାଜୀ). Archived from the original on 18 January 2021. Retrieved 12 November 2019.
↑ DIMITROVA, Elena Kostadinova (22 January 2019). "Fexinidazole Winthrop H-W-2320". European Medicines Agency (in ଇଂରାଜୀ). Archived from the original on 18 January 2021. Retrieved 12 November 2019.
↑ ^୫.୦ ^୫.୧ Deeks, ED (February 2019). "Fexinidazole: First Global Approval". Drugs. 79 (2): 215–220. doi:10.1007/s40265-019-1051-6. PMID 30635838.
↑ Deeks, ED (February 2019). "Fexinidazole: First Global Approval". Drugs. 79 (2): 215–220. doi:10.1007/s40265-019-1051-6. PMID 30635838.
↑ ^୭.୦ ^୭.୧ "Fexinidazole Winthrop (fexinidazole)" (PDF). EMA. Archived from the original (PDF) on 2 January 2021. Retrieved 12 November 2019.
↑ "Fexinidazole Winthrop" (PDF). EMA. Archived from the original (PDF) on 12 November 2019. Retrieved 12 November 2019.
↑ "Fexinidazole Winthrop" (PDF). EMA. Archived from the original (PDF) on 12 November 2019. Retrieved 12 November 2019.
↑ "Fexinidazole Winthrop (fexinidazole)" (PDF). EMA. Archived from the original (PDF) on 2 January 2021. Retrieved 12 November 2019.
↑ Gil, Carmen; Rivas, Luis (2017). Drug Discovery for Leishmaniasis (in ଇଂରାଜୀ). Royal Society of Chemistry. p. 30. ISBN 9781788012584. Archived from the original on 28 August 2021. Retrieved 12 November 2019.
↑ "World Health Organization model list of essential medicines: 21st list 2019". 2019. {{cite journal}}: Cite journal requires |journal= (help)
↑ "Fexinidazole – DNDi". www.dndi.org. Archived from the original on 29 April 2020. Retrieved 12 November 2019.

[FDA_fexinidazole-1] "Fexinidazole: FDA-Approved Drugs". U.S. Food and Drug Administration. Retrieved 16 July 2021.

[Fexinidazole_FDA_label-2] "Fexinidazole tablet". DailyMed. Retrieved 20 August 2021.

[EMA2019Over-3] DIMITROVA, Elena Kostadinova (22 January 2019). "Fexinidazole Winthrop H-W-2320". European Medicines Agency (in ଇଂରାଜୀ). Archived from the original on 18 January 2021. Retrieved 12 November 2019.

[autogen2-4] DIMITROVA, Elena Kostadinova (22 January 2019). "Fexinidazole Winthrop H-W-2320". European Medicines Agency (in ଇଂରାଜୀ). Archived from the original on 18 January 2021. Retrieved 12 November 2019.

[Dee2019-5] ୫.୦ ^୫.୧ Deeks, ED (February 2019). "Fexinidazole: First Global Approval". Drugs. 79 (2): 215–220. doi:10.1007/s40265-019-1051-6. PMID 30635838.

[autogen4-6] Deeks, ED (February 2019). "Fexinidazole: First Global Approval". Drugs. 79 (2): 215–220. doi:10.1007/s40265-019-1051-6. PMID 30635838.

[EMA2019Pub-7] ୭.୦ ^୭.୧ "Fexinidazole Winthrop (fexinidazole)" (PDF). EMA. Archived from the original (PDF) on 2 January 2021. Retrieved 12 November 2019.

[PI2019-8] "Fexinidazole Winthrop" (PDF). EMA. Archived from the original (PDF) on 12 November 2019. Retrieved 12 November 2019.

[autogen3-9] "Fexinidazole Winthrop" (PDF). EMA. Archived from the original (PDF) on 12 November 2019. Retrieved 12 November 2019.

[autogen1-10] "Fexinidazole Winthrop (fexinidazole)" (PDF). EMA. Archived from the original (PDF) on 2 January 2021. Retrieved 12 November 2019.

[11] Gil, Carmen; Rivas, Luis (2017). Drug Discovery for Leishmaniasis (in ଇଂରାଜୀ). Royal Society of Chemistry. p. 30. ISBN 9781788012584. Archived from the original on 28 August 2021. Retrieved 12 November 2019.

[WHO21st-12] "World Health Organization model list of essential medicines: 21st list 2019". 2019. {{cite journal}}: Cite journal requires |journal= (help)

[DND2019-13] "Fexinidazole – DNDi". www.dndi.org. Archived from the original on 29 April 2020. Retrieved 12 November 2019.

[୧]

[୨]

[୩]

[୪]

[୫]

[୬]

[୭]

[୮]

[୯]

[୧୦]

[୧୧]

[୧୨]

[୧୩]